Department of Urology, University Hospital Bern, Bern, Switzerland.
Department of Urology, University Hospital Bern, Bern, Switzerland.
J Urol. 2015 Jan;193(1):173-8. doi: 10.1016/j.juro.2014.07.109. Epub 2014 Aug 5.
Continuous intraoperative norepinephrine infusion combined with restrictive deferred hydration improves surgical field visibility, and significantly decreases intraoperative blood loss and postoperative complications in patients undergoing radical cystectomy and urinary diversion. We determined whether the intraoperative fluid regimen would affect functional results (continence and erectile function) 1 year after orthotopic ileal bladder substitution.
We analyzed a subgroup of 93 patients who received an ileal orthotopic bladder substitute. The subgroup was part of a randomized trial in 167 patients initially allocated to continuous norepinephrine administration starting with 2 μg/kg per hour combined with 1 ml/kg per hour initially and 3 ml/kg per hour crystalloid infusion after cystectomy (norepinephrine/low volume group of 51) or a standard crystalloid infusion of 6 ml/kg per hour throughout surgery (42 controls). We prospectively assessed daytime and nighttime continence, and erectile function 1 year postoperatively in the 93-patient subgroup.
Daytime continence was reported by 44 of 51 patients (86%) in the norepinephrine/low volume group and by 27 of 42 controls (64%) (p = 0.016), and nighttime continence was reported by 38 (75%) and 25 (60%), respectively (p = 0.077). Erectile function recovery was reported by 26 of 33 preoperatively potent patients (79%) in the norepinephrine/low volume group and by 11 of 29 controls (38%) (p = 0.002).
Patients who undergo radical cystectomy and orthotopic bladder substitution with continuous norepinephrine infusion and restrictive hydration during surgery have significantly better daytime continence and erectile function 1 year postoperatively.
连续术中去甲肾上腺素输注联合限制延迟补液可改善手术视野,并显著减少根治性膀胱切除术和尿流改道患者的术中失血和术后并发症。我们确定术中液体方案是否会影响 1 年后肠代膀胱的功能结果(控尿和勃起功能)。
我们分析了接受回肠原位膀胱替代的 93 例患者的亚组。该亚组是 167 例患者的随机试验的一部分,这些患者最初被分配接受持续去甲肾上腺素输注,起始剂量为 2μg/kg/h,联合术后最初 1 小时 1ml/kg/h 和 3ml/kg/h 晶体液输注(去甲肾上腺素/低容量组 51 例)或整个手术期间持续 6ml/kg/h 的标准晶体液输注(对照组 42 例)。我们前瞻性评估了 93 例患者亚组术后 1 年的日间和夜间控尿及勃起功能。
去甲肾上腺素/低容量组 51 例患者中有 44 例(86%)报告日间控尿,对照组 42 例中有 27 例(64%)报告日间控尿(p=0.016),夜间控尿分别为 38 例(75%)和 25 例(60%)(p=0.077)。术前有勃起功能的 33 例患者中有 26 例(79%)在去甲肾上腺素/低容量组报告勃起功能恢复,对照组 29 例中有 11 例(38%)报告勃起功能恢复(p=0.002)。
接受根治性膀胱切除术和原位膀胱替代术的患者,术中持续输注去甲肾上腺素和限制补液,术后 1 年日间控尿和勃起功能明显更好。